Is Tadalafil Associated With Decreased Risk of Major Adverse Cardiac Events or Venous Thromboembolism in Men With Lower Urinary Tract Symptoms?
April 2022
TLDR Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
The study investigated whether tadalafil, a phosphodiesterase type 5 inhibitor (PDE5I) used for treating lower urinary tract symptoms (LUTS), is associated with a decreased risk of major adverse cardiac events (MACE) or venous thromboembolism (VTE). Data from 1,160,681 men were analyzed, with 5,004 using tadalafil but no α-blocker, 327,482 using an α-blocker but no tadalafil, and 6,603 using both. The results showed that tadalafil was associated with a decreased risk of MACE/VTE within a three-year period (OR = 0.59; p<0.0001). This association held true even after controlling for confounding variables. The findings suggest that tadalafil may provide cardiovascular benefits due to its vasodilation and endothelial function effects, warranting further prospective trials to evaluate these benefits in addition to LUTS improvement.